CD274 and melanoma: These results demonstrate that M113PD‐L1+ melanoma tumors expressed PD-L1 in vivo and confirmed that PD-L1 was a relevant tumor target to assess TAT efficacy, while M113WT tumors that did not express PD‐L1 represented a suitable control to evaluate targeting specificity.